Pipeline
Atlantic Healthcare is progressing alicaforsen enema in ulcerative colitis and oral tablet formulations for the treatment of Crohn’s disease and ulcerative colitis.
Renzapride has wide applicability for the treatment of GI dysmotility disorders in rare disease patient populations.
| Product | Preclinical | Phase 1 | Phase 2 a | b |
Phase 3 | Regulatory Approval |
| ALICAFORSEN FOR IBD | |||||
| Enema – Ulcerative Colitis |  |
||||
| Tablet – Crohn’s Disease |  |
||||
| Tablet – Ulcerative Colitis | |
||||
| RENZAPRIDE FOR GI DYSMOTILITY | |||||
| Capsule – Systemic Scleroderma |  |
||||
| Capsule – Cystic Fibrosis | |
||||
| Capsule – Parkinson’s Gastroparesis |  |
||||
Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease (IBD) is caused by a chronic activation of the immune system in the gastrointestinal (GI) tract.
Ulcerative colitis (UC) is an autoimmune disease where the colon (large intestine or bowel) and rectum become inflamed.
Crohn’s Disease is an autoimmune disease which can affect any part of the digestive system, from the mouth to the anus.
Gastrointestinal dysmotility – symptoms of nausea, bloating, abdominal pain and constipation – is a feature of a number of chronic diseases such as Cystic Fibrosis, Systemic Scleroderma and Parkinson’s Disease.